Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSViiV: Dolutegravir in Transgender Women
NCT03033836Phase 4Completed
- Sponsor
- Fundación Huésped
- Start
- Dec 2015
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Fundación Huésped. Started Dec 2015; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03033836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03033836.